Sentio Research

Research services

Evidence-led research (primary, secondary and synthesis) with the clinicians, payers and patients who shape treatment adoption. Delivered as full programmes or specialist fieldwork.

Qualitative market research

In-depth research with the healthcare stakeholders who prescribe, recommend, fund and use medicines.

The question

Before committing to positioning, endpoints or investment, you need to understand treatment-decision drivers, adoption barriers and unmet needs.

What it enables

Clarify how stakeholders will respond before you lock strategy.

Approaches

  • One-to-one interviews
  • Expert interviews
  • Focus groups
  • Online discussion boards
  • Advisory boards
  • Patient, payer and prescriber interviews
  • Treatment-pathway research

Outputs

  • Unmet-needs analysis
  • Prescriber attitudes
  • Treatment-decision drivers
  • Adoption barriers
  • Patient journey insights
  • Message and concept testing
  • Treatment-pathway mapping
  • Clinical endpoint prioritisation

Quantitative market research

Structured research with larger samples to validate hypotheses and quantify market behaviour.

The question

Teams need demand estimates, preference structure and share scenarios grounded in stakeholder response, not desk assumptions alone.

What it enables

Size opportunity and stress-test commercial assumptions with measured evidence.

Approaches

  • Online physician, patient and payer surveys
  • Demand testing
  • Conjoint analysis
  • Discrete-choice exercises
  • Segmentation studies
  • Message prioritisation
  • Target product profile testing

Outputs

  • Demand estimates
  • Prescribing intent
  • Market segmentation
  • Product preference
  • Adoption likelihood
  • Share scenarios
  • Price sensitivity
  • Commercial opportunity sizing

Healthcare fieldwork

Recruit the right participants and collect primary research data, standalone or as part of a full programme.

The question

High-quality healthcare research fails without disciplined research-participant recruitment, screening, compliance and delivery.

What it enables

Secure trustworthy primary data from hard-to-reach respondents.

Approaches

  • Research-participant recruitment for clinicians, payers and patients
  • Eligibility screening and quotas
  • Interview and survey scheduling
  • Honoraria management
  • Translation and transcription
  • Consent and GDPR processes
  • Adverse-event reporting procedures
  • Quality control

Outputs

  • Recordings and transcripts
  • Clean datasets
  • Recruitment logs and screening outcomes
  • Compliance documentation

Commercial opportunity assessment

Evidence-led judgement on whether a drug, asset, indication or market represents a credible commercial opportunity.

The question

Development and licensing teams must decide where to invest, how to position an asset and which assumptions need validation.

What it enables

Choose where to play, and what to validate next.

Approaches

  • Market attractiveness assessment
  • Indication and patient-segment prioritisation
  • Competitor and pipeline analysis
  • Prescriber adoption assessment
  • Treatment-positioning strategy
  • Revenue scenario development
  • Early market sizing
  • Partnering and licensing support

Outputs

  • Prioritised opportunity map
  • Positioning options
  • Assumption register
  • Executive recommendations

Target product profile testing

Test how healthcare professionals and payers respond to different potential product profiles.

The question

Product profiles lock early. You need to know which characteristics drive clinical adoption and commercial value.

What it enables

Define the profile most likely to win with physicians and payers.

Approaches

  • Efficacy, safety and dosing trade-offs
  • Administration and treatment duration
  • Patient population and line of therapy
  • Clinical endpoints and monitoring
  • Combination use
  • Pricing and reimbursement conditions

Outputs

  • Attribute importance
  • Adoption drivers and deal-breakers
  • Profile recommendations
  • Evidence implications

Pricing and market access

Clarify what evidence payers and reimbursement bodies would require, and where access barriers sit.

The question

Strong clinical stories fail commercially without a clear view of willingness to reimburse and evidence thresholds.

What it enables

Align development and commercial plans with payer reality.

Approaches

  • Willingness to reimburse
  • Evidence requirements
  • Pricing thresholds
  • Access restrictions and eligible populations
  • Budget-impact concerns
  • Health-economic value
  • HTA considerations
  • Market-specific access pathways

Outputs

  • Access barriers and levers
  • Evidence priorities
  • Pricing corridors
  • Country-specific guidance

Competitive intelligence

Evaluate the commercial and clinical landscape around a product or therapeutic area.

The question

Differentiation, market-entry risk and scenario planning need to be grounded in current competitive dynamics.

What it enables

Anticipate competitors and sharpen your position.

Approaches

  • Competitor pipeline mapping
  • Product benchmarking
  • Clinical-trial comparisons
  • Mechanism-of-action analysis
  • Differentiation assessment
  • Market-entry risk reviews
  • Competitive positioning
  • Scenario planning

Outputs

  • Competitive landscape maps
  • Differentiation narratives
  • Risk registers
  • Scenario packs for decision forums

Discuss a research question

Share your contact details and the question you need evidence to answer.

Our operating framework is being developed with reference to applicable market-research, data-protection and pharmaceutical industry guidance. Project-specific requirements are agreed before fieldwork begins.